

4. Kawasaki, T., Deka, C. S., Bartter, F. C. & Smith, H. *Am. J. Med.* **64**, 193–198 (1978).
5. Fujita, T., Henry, W. L., Bartter, F. C., Lake, C. R. & Delea, C. S. *Am. J. Med.* **69**, 334–344 (1980).
6. Kimura, G., Frem, G. J. & Brenner, B. M. *Curr. Nephrol. Hypertension* **3**, 1–12 (1994).
7. Drewett, J. & Garbers, D. L. *Endocrine Rev.* **15**, 135–162 (1994).
8. John, S. W. M. et al. *Science* **267**, 679–681 (1995).
9. Chinkers, M. et al. *Nature* **338**, 78–83 (1989).
10. Atlas, S. A. & Laragh, J. H. in *Hypertension: Pathophysiology, Diagnosis, and Management* (eds Laragh, J. H. & Brenner, B. M.) 861–883 (Raven, New York, 1990).
11. Ballermann, B. J., Zeidel, M. L., Gunning, M. E. & Brenner, B. M. in *The Kidney* (eds Brenner, B. M. & Rector, F. C.) 510–583 (Saunders, Philadelphia, 1991).
12. Sudoh, T., Kangawa, K., Minamino, N. & Matsuo, H. *Nature* **332**, 78–81 (1988).
13. Suga, S.-I. et al. *Endocrinology* **130**, 229–239 (1992).
14. Ogawa, Y. et al. *J. clin. Invest.* **93**, 1911–1921 (1994).
15. Fuller, F. et al. *J. biol. Chem.* **263**, 9395–9401 (1988).
16. Nussenzveig, D. R., Lewicki, J. A. & Maack, T. J. *J. biol. Chem.* **265**, 20952–20958 (1990).
17. Levin, E. R. *Am. J. Physiol.* **264**, E483–E489 (1993).
18. Anand-Srivastava, M. B. & Trachte, G. J. *Pharmac. Rev.* **45**, 455–497 (1993).
19. Koller, K. J. et al. *Science* **252**, 120–123 (1991).
20. Steinhilper, M. E., Cochran, K. L. & Field, L. J. *Hypertension* **16**, 301–307 (1990).
21. Dietz, J. R., Vesely, D. L. & Nazian, S. J. *Clin. exp. Pharmac. Hypertension* **21**, 599–606 (1994).
22. Sullivan, J. M. & Ratts, T. E. *Hypertension* **11**, 717–723 (1988).
23. Yamaguchi, M., Rutledge, L. J. & Garbers, D. L. *J. biol. Chem.* **265**, 20414–20420 (1990).
24. Ishibashi, S. et al. *J. clin. Invest.* **92**, 883–893 (1993).
25. Ramirez-Solis, R., Davis, A. C. & Bradley, A. *Meth. Enzym.* **225**, 855–878 (1993).
26. Soriano, P., Montgomery, C., Geske, R. & Bradley, A. *Cell* **64**, 693–702 (1991).
27. Krege, J. H., Hodgson, J. B., Hagaman, J. R. & Smithies, O. *Hypertension* **25**, 1111–1115 (1995).
28. Fukamizu, A. et al. *J. biol. Chem.* **268**, 11617–11621 (1993).

ACKNOWLEDGEMENTS. M.J.L., S.K.-F.W. and A.B. are equivalent authors on the manuscript. This work was supported in part by grants from the NIH.

A sex difference in the human brain and its relation to transsexuality

Jiang-Ning Zhou*, Michel A. Hofman*,
Louis J. G. Gooren† & Dick F. Swaab*‡

* Graduate School Neurosciences Amsterdam,
Netherlands Institute for Brain Research, Meibergdreef 33,
1105 AZ Amsterdam ZO, The Netherlands

† Department of Endocrinology, Free University Hospital,
1007 MB Amsterdam, The Netherlands

TRANSSEXUALS have the strong feeling, often from childhood onwards, of having been born the wrong sex. The possible psychogenic or biological aetiology of transsexuality has been the subject of debate for many years^{1,2}. Here we show that the volume of the central subdivision of the bed nucleus of the stria terminalis (BSTc), a brain area that is essential for sexual behaviour^{3,4}, is larger in men than in women. A female-sized BSTc was found in male-to-female transsexuals. The size of the BSTc was not influenced by sex hormones in adulthood and was independent of sexual orientation. Our study is the first to show a female brain structure in genetically male transsexuals and supports the hypothesis that gender identity develops as a result of an interaction between the developing brain and sex hormones^{5,6}.

Investigation of the genetics, gonads, genitalia or hormone level of transsexuals has not, so far, produced any results that explain their status^{1,2}. In experimental animals, however, the same gonadal hormones that prenatally determine the morphology of the genitalia also influence the morphology and function of the brain in a sexually dimorphic fashion^{6,7}. This led to the hypothesis that sexual differentiation of the brain in transsexuals might not have followed the line of sexual differentiation of the body as a whole. In the past few years, several anatomical differences in relation to sex and sexual orientation have been observed in the human hypothalamus (see ref. 6 for a review), but so far no neuroanatomical investigations have been made in relation to the expression of cross-gender identity (transsexuality).




FIG. 1 Schematic frontal section through two subdivisions of the bed nucleus of the stria terminalis (BST). III, third ventricle; AC, anterior commissure; BSTc and BSTv, central and ventral subdivisions of the BST; Fx, fornix; IC, internal capsule; LV, lateral ventricle; NBM, nucleus basalis of Meynert; OT, optic tract; PVN, paraventricular nucleus; SDN, sexually dimorphic nucleus; SON, supraoptic nucleus.

We have studied the hypothalamus of six male-to-female transsexuals (T1–T6); this material was collected over the past eleven years. We searched for a brain structure that was sexually dimorphic but that was not influenced by sexual orientation, as male-to-female transsexuals may be 'oriented' to either sex with respect to sexual behaviour. Our earlier observations showed that the paraventricular nucleus (PVN), sexually dimorphic nucleus (SDN) and supraoptic nucleus (SON) did not meet these criteria (ref. 6 and unpublished data). Although there is no accepted animal model for gender-identity alteration, the bed nucleus of the stria terminalis (BST) turned out to be an appropriate candidate to study for the following reasons. First, it is known that the BST plays an essential part in rodent sexual behaviour^{3,4}. Not only have oestrogen and androgen receptors been found in the BST^{8,9}, it is also a major aromatization centre in the developing rat brain¹⁰. The BST in the rat receives projections mainly from the amygdala and provides a strong input in the preoptic-hypothalamic region^{11,12}. Reciprocal connections between hypothalamus, BST and amygdala are also well documented in experimental animals^{13–15}. In addition, sex differences in the size and cell number of the BST have been described in rodents which are influenced by gonadal steroids in development^{16–18}. Also, in humans a particular caudal part of the BST (BNST-dspm) has been reported to be 2.5 times larger in men than in women¹⁹.

The localization of the BST is shown in Fig. 1. The central part of the BST (BSTc) is characterized by its somatostatin cells and vasoactive intestinal polypeptide (VIP) innervation²⁰. We measured the volume of the BSTc on the basis of its VIP innervation (Fig. 2). The BSTc volume in heterosexual men ($2.49 \pm 0.16 \text{ mm}^3$) was 44% larger than in heterosexual women ($1.73 \pm 0.13 \text{ mm}^3$) ($P < 0.005$) (Fig. 3). The volume of the BSTc of heterosexual and homosexual men did not differ in any statist-

‡ To whom correspondence should be addressed.




FIG. 2 Representative sections of the BSTc innervated by vasoactive intestinal polypeptide (VIP). a, Heterosexual man; b, heterosexual woman; c, homosexual man; d, male-to-female transsexual. Scale bar, 0.5 mm. LV, lateral ventricle. Note there are two parts of the BST in a and b: small medial subdivision (BSTm) and large oval-sized central subdivision (BSTc).

ically significant way ($2.81 \pm 0.20 \text{ mm}^3$) ($P=0.26$). The BSTc was 62% larger in homosexual men than in heterosexual women ($P<0.005$). AIDS did not seem to influence the size of the BSTc: the BSTc size of two heterosexual AIDS-infected women and three heterosexual AIDS-infected men remained well within the range of the corresponding reference group (Fig. 3). The AIDS-infected heterosexuals were therefore included in the corresponding reference group for statistical purposes. A small volume of the BSTc ($1.30 \pm 0.23 \text{ mm}^3$) was found in the male-to-female transsexuals (Fig. 3). Its size was only 52% of that found in the reference males ($P<0.005$) and 46% of the BSTc of homosexual males ($P<0.005$). Although the mean BSTc volume in the transsexuals was even smaller than that in the female group, the difference did not reach statistical significance ($P=0.13$). The volume of the BSTc was not related to age in any of the reference groups studied ($P>0.15$), indicating that the observed small size of the BSTc in transsexuals was not due to the fact that they were, on average, 10 to 13 years older than the hetero- and homosexual men.

The BST plays an essential role in masculine sexual behaviour and in the regulation of gonadotrophin release, as shown by studies in the rat^{3,4,21}. There has been no direct evidence that the BST has such a role in human sexual behaviour, but our demonstration of a sexually dimorphic pattern in the size of the human BSTc, which is in agreement with the previously described sex difference in a more caudal part of the human BST (BNST-dspm)¹⁹, indicates that this nucleus may also be involved in human sexual or reproductive functions. It has been proposed that neurochemical sex differences in the rat BST may be due to effects of sex hormones on the brain during development and in adulthood^{22,23}. Our data from humans however, indicate that BSTc volume is not affected by varying sex hormone levels in adulthood. The BSTc volume of a 46-year-old woman, who had suffered for at least one year from a tumour of the adrenal cortex that produced very high blood levels of androstenedione and testosterone, was within the range of that of other women (Fig. 3; S1). Furthermore, two postmenopausal women (aged over 70 years) showed a completely normal female-sized BSTc (Fig. 3;




FIG. 3 Volume of the BSTc innervated by VIP fibres in presumed heterosexual males (M), homosexual males (HM), presumed heterosexual females (F) and male-to-female transsexuals (TM). The six transsexuals are numbered T1–T6. The patients with abnormal sex hormone levels are numbered S1–S4. M1 and M2, postmenopausal women. Bars indicate mean $\pm$ s.e.m. Open symbols: individuals who died of AIDS. **METHODS.** Brains of 42 subjects matched for age, postmortem time and duration of formalin fixation were investigated. The autopsy was performed after obtaining permission. For immunocytochemical staining of VIP, paraffin sections were hydrated and rinsed in Tris-buffered-saline TBS: 0.05 M Tris, 0.9% NaCl, pH 7.6). Sections were incubated with 200 μ l anti-VIP 1:1,000 in 0.5% Triton in TBS overnight at 4 °C. Immunocytochemical and morphometric procedures have been described^{25–27}. In brief, serial 6 μ m sections of the BSTc were studied by means of a digitizer (Calcomp 2000) connected to a HP-UX 9.0, using a Zeiss microscope equipped with a 2.5 $\times$ objective and with 10 $\times$ (PLAN) oculars. Staining was performed on every fiftieth section with anti-VIP. The rostral and caudal borders of the BSTc were assessed by staining every tenth section in the area. The volume of the BSTc was determined by integrating all the area measurements of the BSTc sections that were innervated by VIP fibres. In a pilot study, the size of the BSTc was measured on both sides in 8 subjects (5 females and 3 males) and no left–right asymmetries were observed: the left BSTc (1.71 ± 0.16 mm³) was comparable in size to that of the right BSTc (1.83 ± 0.30 mm³) ($P=0.79$). No asymmetry was observed in the BNST-dspm either¹⁹. The rest of our study was therefore performed on one side of the brain only. Brain weight of the male transsexuals ($1,385 \pm 78$ g) was not different from that of the reference males ($1,453 \pm 25$ g) ($P=0.61$) or that of the females ($1,256 \pm 35$ g) ($P=0.23$). The causes of death of the transsexuals were suicide (T1), cardiovascular disease (T2,T6), sarcoma (T3), AIDS, pneumonia, pericarditis (T4) and hepatic failure (T5). Sexual orientation of the subjects of the reference group (12 men and 11 women) was generally not known, but most of them were presumed heterosexual. Sexual orientation of 9 homosexuals was registered in the clinical records²⁸. Differences among the groups were tested two-tailed using the Mann–Whitney *U*-test. A 5% level of significance was used in all statistical tests.

M1, M2). As all the transsexuals had been treated with oestrogens, the reduced size of the BSTc could possibly have been due to the presence of high levels of oestrogen in the blood. Evidence against this comes from the fact that transsexuals T2 and T3 both showed a small, female-like BSTc (Fig. 3), although T2 stopped taking oestrogen about 15 months before death because her prolactin levels were too high and T3 stopped hormone treatment as a sarcoma was found about 3 months before death; also a 31-year-old man who suffered from a feminizing adrenal tumour which induced high blood levels of oestrogen, nevertheless had a very large BSTc (Fig. 3; S2).

Our results might also be explained if the female-sized BSTc in the transsexual group was due to a lack of androgens, because they had all been orchidectomized except for T4. We therefore studied two other men who had been orchidectomized because of cancer of the prostate (one and three months before death: S4 and S3, respectively), and found that their BSTc sizes were

at the high end of the normal male range. The BSTc size of the single transsexual who had not been orchidectomized (T4) ranged in the middle of the transsexual scores (Fig. 3). Not only were five of the transsexuals orchidectomized, they all used the antiandrogen compound cyproterone acetate (CPA). A CPA effect on the BSTc does not seem likely, because T6 had not taken CPA for the past 10 years, and T3 took no CPA during the 2 years before death and still had a female-sized BSTc.

In summary, our observations suggest that the small size of the BSTc in male-to-female transsexuals cannot be explained by differences in adult sex hormone levels, but is established during development by an organizing action of sex hormones, an idea supported by the fact that neonatal gonadectomy of male rats and androgenization of female rats induces significant changes in the number of neurons of the BST and suppresses its sexual dimorphism^{17,18}.

Considered together with information from animals, then our study supports the hypothesis that gender identity alterations may develop as a result of an altered interaction between the development of the brain and sex hormones^{5,6}. The direct action of genetic factors should also be considered on the basis of animal experiments²⁴.

We found no relationship between BSTc size and the sexual orientation of transsexuals, that is, whether they were male-oriented (T1,T6), female-oriented (T3,T2,T5) or both (T4). Furthermore, the size of the BSTc of heterosexual men and homosexual men did not differ, which reinforced the idea that the reduced BSTc size is independent of sexual orientation. In addition, there was no difference in BSTc size between early-onset (T2,T5,T6) and late-onset transsexuals (T1,T3), indicating that the decreased size is related to the gender identity alteration *per se* rather than to the age at which it becomes apparent. Interestingly, the very small BSTc in transsexuals appears to be a very local brain difference. We failed to observe similar changes in three other hypothalamic nuclei, namely PVN, SDN or SCN in the same individuals (unpublished data). This might be due to the fact that these nuclei do not all develop at the same time, or to a difference between these nuclei and the BST with respect to the presence of sex hormone receptors or aromatase. We are now studying the distribution of sex hormone receptors and the aromatase activity in various hypothalamic nuclei in relation to sexual orientation and gender. □

Received 23 May; accepted 28 August 1995.

1. Money, J. & Gaskin, R. J. *Int. J. Psychiatry* **9**, 249 (1970/71).
2. Gooren, L. J. G. *Psychoneuroendocrinology* **15**, 3–14 (1990).
3. Kawakami, M. & Kimura, F. *Endocrinol. Jap.* **21**, 125–130 (1974).
4. Emery, D. E. & Sachs, B. D. *Physiol. Behav.* **17**, 803–806 (1976).
5. Editorials *Lancet* **338**, 603–604 (1991).
6. Swaab, D. F. & Hofman, M. A. *Trends Neurosci.* **18**, 264–270 (1995).
7. Money, J., Schwartz, M. & Lewis, V. G. *Psychoneuroendocrinology* **9**, 405–414 (1984).
8. Sheridan, P. J. *Endocrinology* **104**, 130–136 (1979).
9. Commins, D. & Yahr, D. J. *comp. Neurol.* **231**, 473–489 (1985).
10. Jakab, R. L., Horvath, T. L., Leran, C., Harada, N. & Naftolin, F. J. *Steroid Biochem. molec. Biol.* **44**, 481–498 (1993).
11. Eiden, E. L., Hökfelt, T., Brownstein, M. J. & Palkovits, M. *Neuroscience* **15**, 999–1013 (1985).
12. De Olmos, J. S. in *The Human Nervous System* (ed. Paxinos, G.) 597–710 (Academic, San Diego, 1990).
13. Woodhams, P. L., Roberts, G. W., Polak, J. M. & Crow, T. J. *Neuroscience* **8**, 677–703 (1983).
14. Simerly, R. B. *Trends Neurosci.* **13**, 104–110 (1990).
15. Arluison, M. et al. *Brain Res. Bull.* **34**, 319–337 (1994).
16. Bleier, R., Byne, W. & Siggekow, I. J. *comp. Neurol.* **212**, 118–130 (1982).
17. Del Abril, A., Segovia, S. & Guillamón, A. *Dev. Brain Res.* **32**, 295–300 (1987).
18. Guillamón, A., Segovia, S. & Del Abril, A. *Dev. Brain Res.* **44**, 281–290 (1988).
19. Allen, L. A. & Gorski, R. A. J. *comp. Neurol.* **302**, 697–706 (1990).
20. Walter, A., Mai, J. K., Lanta, L. & Görcs, T. J. *Chem. Neuroanat.* **4**, 281–298 (1991).
21. Claro, F., Segovia, S., Guillamón, A. & Del Abril, A. *Brain Res. Bull.* **36**, 1–10 (1995).
22. Simerly, R. B. & Swanson, L. W. *Proc. natn. Acad. Sci. U.S.A.* **84**, 2087–2091 (1987).
23. De Vries, G. J. N. *Neuroendocr.* **20**, 1–13 (1990).
24. Pilgrim, C. & Reiser, I. *Horm. metab. Res.* **24**, 353–359 (1992).
25. Swaab, D. F., Zhou, J. N., Ehlhart, T. & Hofman, M. A. *Brain Res.* **79**, 249–259 (1994).
26. Zhou, J. N., Hofman, M. A. & Swaab, D. F. *Neurobiol. Aging* **16**, 571–576 (1995).
27. Zhou, J. N., Hofman, M. A. & Swaab, D. F. *Brain Res.* **672**, 285–288 (1995).
28. Swaab, D. F. & Hofman, M. A. *Brain Res.* **537**, 141–148 (1990).

ACKNOWLEDGEMENTS. We thank B. Fisser, H. Stoffels, G.v.d. Meulen, T. Eikelboom and W. T. P. Verwey for their help, and R. M. Buijs, M. A. Corner, E. Fliers, A. Walter and F. W. van Leeuwen for their comments. Brain material was provided by the Netherlands Brain Bank (coordinator R. Ravid). This work was supported by NWO.